The ASCO 2016 Genitourinary Cancers Symposium
The annual Genitourinary Cancers Symposium of the American Society of Clinical Oncology was held from Jan. 7 to 9 in San Francisco and attracted more than 2,000 participants from around the world. The conference highlighted recent advances in the diagnosis, prevention, and management of genitourinary cancers, including prostate, kidney, bladder, and testicular cancers.
One group of researchers found that statin use is associated with a trend toward longer duration of abiraterone acetate treatment (AA) in men with castration-resistant prostate cancer (CRPC).
Lauren Christine Harshman, M.D., from the Dana-Farber Cancer Institute in Boston, and colleagues queried their institutional clinical database for patients treated with AA for CRPC to examine whether statins compete with AA for influx by the transporter SLCO2B1, which could negatively impact drug efficacy.
The researchers found that 96 percent of the 224 patients eligible for analysis had metastatic disease at the time of AA initiation; 41 percent were statin users. The median AA duration was 10.7 months, with a trend toward longer duration on AA in statin users (14.2 versus 9.2 months; hazard ratio, 0.79; 95 percent confidence interval, 0.57 to 1.09). The correlation between statin use and AA duration was not affected by prior docetaxel or enzalutamide use, or by site of metastases (P = 0.18).
Several authors disclosed financial ties to the pharmaceutical industry.
In another presentation, researchers found that a 52-gene signature can predict metastasis-free survival in adjuvant hormone treated men with prostate cancer.
R. Jeffrey Karnes, M.D., from the Mayo Clinic in Rochester, Minn., and colleagues obtained expression profiles for 1,023 prostate cancer patients treated with radical prostatectomy from the Decipher GRID database. The patients were split into training and validation sets (529 and 494 patients, respectively) and stratified by androgen deprivation therapy (ADT) receipt (243 patients) or no ADT (780 patients). A 52-gene ADT resistance signature (ARS) was developed.
The researchers found that the ARS was predictive of metastasis in cohorts receiving adjuvant ADT (10-year metastasis-free survival C-index, 0.69, versus 0.45 in patients not treated with ADT). In a separate cohort of ADT untreated patients, ARS was not prognostic (C-index, 0.53). Among ADT treated patients, low ARS scores were associated with a 10-year metastasis-free survival of 87 percent, compared with 70 percent for those with high ARS scores (P < 0.001).
“A 52-gene ADT resistance signature was developed which showed significant differences in metastasis-free survival among adjuvant hormone treated but not untreated patients,” the authors wrote in the study abstract.
Several authors disclosed financial ties to GenomeDx.
For the treatment of patients with metastatic urothelial cancer (mUC), researchers evaluated the efficacy and safety of the combination of gemcitabine + cisplatin + ipilimumab (GCIpi). Two cycles of gemcitabine plus cisplatin (GC) alone followed by four cycles of GCIpi were administered to 36 patients with mUC.
The investigators found that median progression-free survival was eight months and median follow-up was 10.4 months. In terms of immunomodulatory effects, the investigators found that GC had no significant effect on circulating immune cell subsets; however, Ipi had an impact on circulating immune cell subsets, significantly expanding circulating CD4 and CD8 T cells.
“A phased schedule of GC plus immune checkpoint blockade was feasible in patients with mUC. Ipi induced immunomodulatory effects despite concurrent chemotherapy,” the authors wrote in the study abstract. “Survival data are not yet mature. Ongoing analyses are exploring the impact of GC alone, and GCIpi, on antigen-specific T cell immunity and correlating such findings with ‘outlier’ survival times.”
Several authors disclosed financial ties to the pharmaceutical industry.
ASCO: CTC Heterogeneity Predicts Hormone Tx Response in mCRPC
WEDNESDAY, Jan. 6, 2016 (HealthDay News) — For patients with metastatic castration-resistant prostate cancer (mCRPC), phenotypic and genomic heterogeneity in circulating tumor cells (CTCs) is associated with response to hormone therapy, according to a study scheduled to be presented at the American Society of Clinical Oncology’s annual Genitourinary Cancers Symposium, held from Jan. 7 to 9 in San Francisco.
ASCO: Aspirin Use Linked to Lower Risk of Lethal Prostate CA
TUESDAY, Jan. 5, 2016 (HealthDay News) — For men with prostate cancer, regular aspirin use after diagnosis is associated with reduced risk for developing lethal prostate cancer, according to a study scheduled to be presented at the American Society of Clinical Oncology’s annual Genitourinary Cancers Symposium, held from Jan. 7 to 9 in San Francisco.
ASCO: Cabozantinib Improves Progression-Free Survival in RCC
TUESDAY, Jan. 5, 2016 (HealthDay News) — For patients with advanced renal cell carcinoma, cabozantinib is associated with improved progression-free survival (PFS), with consistent improvement across all patient subgroups, according to a study scheduled to be presented at the American Society of Clinical Oncology’s annual Genitourinary Cancers Symposium, held from Jan. 7 to 9 in San Francisco.
Copyright © 2016 HealthDay. All rights reserved.
